CYP2C19 *2/*2 Genotype is a Risk Factor for Multi-Site Arteriosclerosis: A Hospital-Based Cohort Study

References

• Turana Y, Tengkawan J. Hypertension and stroke in Asia: a comprehensive review from HOPE Asia. J Clin Hypertens. 2021;23(3):513–521. doi:10.1111/jch.14099
   Web of Science ®Google Scholar
• Ji E, Lee S. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases. Int J Mol Sci. 2021;22(11):5770. doi:10.3390/ijms22115770
   PubMed Web of Science ®Google Scholar
• Zhang ZZ, Wang G, Yin SH, Yu XH. C1q Tumor Necrosis Factor-Related Protein 1: a Promising Therapeutic Target for Atherosclerosis. J Cardiovasc Pharmacol. 2022;79(3):273–280. doi:10.1097/FJC.0000000000001186
   PubMed Web of Science ®Google Scholar
• Jing L, Shu-Xu D, Yong-Xin R. A review: pathological and molecular biological study on atherosclerosis. Clin Chim Acta. 2022;531:217–222. doi:10.1016/j.cca.2022.04.012
   PubMed Web of Science ®Google Scholar
• Gutierrez J, Turan TN, Hoh BL, Chimowitz MI. Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2022;21(4):355–368. doi:10.1016/S1474-4422(21)00376-8
   PubMed Web of Science ®Google Scholar
• Marchio P, Guerra-Ojeda S, Vila JM. Targeting Early Atherosclerosis: a Focus on Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2019;2019:8563845. doi:10.1155/2019/8563845
   PubMed Web of Science ®Google Scholar
• Shamaki GR, Markson F, Soji-Ayoade D, Agwuegbo CC, Bamgbose MO, Tamunoinemi BM. Peripheral Artery Disease: a Comprehensive Updated Review. Curr Probl Cardiol. 2022;47(11):101082. doi:10.1016/j.cpcardiol.2021.101082
   PubMed Web of Science ®Google Scholar
• Park TS, Devi S, Sharma A, Kim GT, Cho KH. De Novo Sphingolipid Biosynthesis in Atherosclerosis. Adv Exp Med Biol. 2022;1372:31–46. doi:10.1007/978-981-19-0394-6_3
   PubMedGoogle Scholar
• Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021;128(12):1818–1832. doi:10.1161/CIRCRESAHA.121.318535
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular Disease: reappraisal of the Current Clinical Landscape. Circ Cardiovasc Interv. 2019;12(12):e007385. doi:10.1161/CIRCINTERVENTIONS.119.007385
   PubMed Web of Science ®Google Scholar
• Zhou F, Tang J, Li P, Liao B, Qin C. Distribution of cerebral artery stenosis and risk factors in ethnic Zhuang and Han patients with ischemic stroke in Guangxi province. Ann Palliat Med. 2020;9(2):256–263. doi:10.21037/apm.2020.02.32
   PubMed Web of Science ®Google Scholar
• Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol. 2020;27(4):394–406. doi:10.1177/2047487319869400
   PubMed Web of Science ®Google Scholar
• Abraham G, Rutten-Jacobs L, Inouye M. Risk Prediction Using Polygenic Risk Scores for Prevention of Stroke and Other Cardiovascular Diseases. Stroke. 2021;52(9):2983–2991. doi:10.1161/STROKEAHA.120.032619
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang Y, Guengerich FP. Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications. J Biol Chem. 2020;295(3):833–849. doi:10.1074/jbc.REV119.008758
   PubMed Web of Science ®Google Scholar
• Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19(8):2057–2070. doi:10.22034/APJCP.2018.19.8.2057
   PubMedGoogle Scholar
• Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–967. doi:10.1002/cpt.2526
   PubMed Web of Science ®Google Scholar
• Fisslthaler B, Fleming I, Busse R. EDHF: a cytochrome P450 metabolite in coronary arteries. Semin Perinatol. 2000;24(1):15–19. doi:10.1016/s0146-0005(00)80048-8
   PubMed Web of Science ®Google Scholar
• Chawengsub Y, Gauthier KM, Campbell WB. Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol. 2009;297(2):H495–507. doi:10.1152/ajpheart.00349.2009
   PubMed Web of Science ®Google Scholar
• Fleming I, Michaelis UR, Bredenkötter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001;88(1):44–51. doi:10.1161/01.res.88.1.44
   PubMed Web of Science ®Google Scholar
• Malekmohammad K, Sewell RDE. Antioxidants and Atherosclerosis: mechanistic Aspects. Biomolecules. 2019;9(8):301. doi:10.3390/biom9080301
   PubMed Web of Science ®Google Scholar
• Negre-Salvayre A, Guerby P, Gayral S, Laffargue M, Salvayre R. Role of reactive oxygen species in atherosclerosis: lessons from murine genetic models. Free Radic Biol Med. 2020;149:8–22. doi:10.1016/j.freeradbiomed.2019.10.011
   PubMed Web of Science ®Google Scholar
• Ma L, Yuan Y, Li J, Yu C, Zhao J. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. Int J Immunogenet. 2020;47(6):539–545. doi:10.1111/iji.12511
   PubMed Web of Science ®Google Scholar
• Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022;88(7):3288–3296. doi:10.1111/bcp.15268
   PubMed Web of Science ®Google Scholar
• Huang S, Yang S, Ly S, et al. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review. Eur J Clin Pharmacol. 2022;78(8):1217–1225. doi:10.1007/s00228-022-03346-7
   PubMed Web of Science ®Google Scholar
• Jafrin S, Naznin NE, Reza MS, Aziz MA, Islam MS. Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: an ethnicity-based updated meta-analysis. Eur J Intern Med. 2021;90:49–65. doi:10.1016/j.ejim.2021.05.022
   PubMed Web of Science ®Google Scholar
• Wang T, Zhao T, Bao S, et al. CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019. Medicine. 2020;99(29):e20582. doi:10.1097/MD.0000000000020582
   PubMed Web of Science ®Google Scholar
• Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010;16(5):579–583. doi:10.1177/1076029610364522
   PubMed Web of Science ®Google Scholar
• Hokimoto S, Tabata N, Akasaka T, et al. Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease. J Cardiovasc Pharmacol. 2015;65(2):148–152. doi:10.1097/FJC.0000000000000171
   PubMed Web of Science ®Google Scholar
• Patel PD, Vimalathas P, Niu X, et al. CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease. J Stroke Cerebrovasc Dis. 2021;30(2):105464. doi:10.1016/j.jstrokecerebrovasdis.2020.105464
   PubMed Web of Science ®Google Scholar
• Kubota M, Yoneda M, Watanabe H, Egusa G. Progression of Carotid Atherosclerosis in Two Japanese Populations with Different Lifestyles. J Atheroscler Thromb. 2017;24(10):1069–1074. doi:10.5551/jat.39578
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang X, Zhang Q, et al. Relationship Between Dietary Patterns and Carotid Atherosclerosis Among People Aged 50 Years or Older: a Population-Based Study in China. Front Nutr. 2021;8:723726. doi:10.3389/fnut.2021.723726
   PubMed Web of Science ®Google Scholar
• Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290–296. doi:10.1159/000343145
   PubMed Web of Science ®Google Scholar
• Qiao Y, Guallar E, Suri FK, et al. MR Imaging Measures of Intracranial Atherosclerosis in a Population-based Study. Radiology. 2016;280(3):860–868. doi:10.1148/radiol.2016151124
   PubMed Web of Science ®Google Scholar
• Wu FZ, Wu MT. 2014 SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2015;9(2):e3. doi:10.1016/j.jcct.2015.01.003
   PubMedGoogle Scholar
• Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results From the China Hypertension Survey, 2012-2015. Circulation. 2018;137(22):2344–2356. doi:10.1161/CIRCULATIONAHA.117.032380
   PubMed Web of Science ®Google Scholar
• Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017;317(24):2515–2523. doi:10.1001/jama.2017.7596
   PubMed Web of Science ®Google Scholar
• Cai N, Li C, Gu X, et al. CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study. BMC Cardiovasc Disord. 2023;23(1):185. doi:10.1186/s12872-023-03207-w
   PubMed Web of Science ®Google Scholar
• Reynald RL, Sansen S, Stout CD, Johnson EF. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem. 2012;287(53):44581–44591. doi:10.1074/jbc.M112.424895
   PubMed Web of Science ®Google Scholar
• He L, Chen S, Li J, et al. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese. Clin Exp Pharmacol Physiol. 2020;47(10):1659–1663. doi:10.1111/1440-1681.13357
   PubMed Web of Science ®Google Scholar
• Lee YC, Liao YC, Chang FC, Huang HC, Tsai JY, Chung CP. Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population. J Chin Med Assoc. 2019;82(6):469–472. doi:10.1097/JCMA.0000000000000101
   PubMed Web of Science ®Google Scholar
• Vu NP, Nguyen HTT, Tran NTB, et al. CYP2C19 genetic polymorphism in the Vietnamese population. Ann Hum Biol. 2019;46(6):491–497. doi:10.1080/03014460.2019.1687750
   PubMed Web of Science ®Google Scholar
• Sukprasong R, Chuwongwattana S, Koomdee N, et al. Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. Sci Rep. 2021;11(1):12343. doi:10.1038/s41598-021-90969-y
   PubMed Web of Science ®Google Scholar
• Vidović S, Škrbić R, Stojiljković MP, et al. Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina. Arh Hig Rada Toksikol. 2021;72(3):129–134. doi:10.2478/aiht-2021-72-3499
   PubMedGoogle Scholar
• Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007;21(4):419–426. doi:10.1111/j.1472-8206.2007.00510.x
   PubMed Web of Science ®Google Scholar
• Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347–361. doi:10.1038/sj.clpt.6100482
   PubMed Web of Science ®Google Scholar
• Afilal D, Basselam MA, Brakez Z, Chouham S, Brehm A, Izaabel EH. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population. Genet Test Mol Biomarkers. 2017;21(5):298–304. doi:10.1089/gtmb.2016.0304
   PubMed Web of Science ®Google Scholar
• Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009;10:124. doi:10.1186/1471-2350-10-124
   PubMed Web of Science ®Google Scholar
• Khalil BM, Shahin MH, Solayman MH, et al. Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci. 2016;9(1):23–28. doi:10.1111/cts.12383
   PubMed Web of Science ®Google Scholar
• Saber MM, Boroumand M, Behmanesh M. Investigation of CYP2C19 allele and genotype frequencies in Iranian population using experimental and computational approaches. Thromb Res. 2014;133(2):272–275. doi:10.1016/j.thromres.2013.11.005
   PubMed Web of Science ®Google Scholar
• Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep. 2011;38(8):5449–5452. doi:10.1007/s11033-011-0700-y
   PubMed Web of Science ®Google Scholar
• Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol. 2005;61(3):179–184. doi:10.1007/s00228-004-0890-5
   PubMed Web of Science ®Google Scholar
• de Andrés F, Altamirano-Tinoco C, Ramírez-Roa R, Montes-Mondragón CF, Dorado P. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. Pharmacogenomics J. 2021;21(2):140–151. doi:10.1038/s41397-020-00190-9
   PubMed Web of Science ®Google Scholar
• Pastore I, Bolla AM, Montefusco L, et al. The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents. Int J Mol Sci. 2020;21(14):4928. doi:10.3390/ijms21144928
   PubMed Web of Science ®Google Scholar
• Pabon M, Cheng S. Sex Differences in Peripheral Artery Disease. Circ Res. 2022;130(4):496–511. doi:10.1161/CIRCRESAHA.121.320702
   PubMed Web of Science ®Google Scholar